{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:01:55Z","timestamp":1794589315917,"version":"4.9.1"},"reference-count":92,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is a heterogeneous disease with survival ranging from months to decades. The goal of \u2018cure\u2019 remains elusive for most patients, but has been shown to be possible, with durable remission and a transition to a plateau phase (analogous to monoclonal gammopathy of uncertain significance\/smoldering myeloma). In this review, two representative cases set the stage to illustrate how this might be possible and what still needs to be determined to achieve functional disease control over a prolonged period. Several developments have emerged, such as improved diagnostics including the definitions and use of SLiM-CRAB criteria and measurable residual disease (MRD) with whole-genome\/single-cell sequencing as well as other correlates to better understand disease biology. These advances enable earlier detection, more accurate risk stratification and improved personalized treatment strategies by facilitating analysis of genetic alterations and clonal heterogeneity. Whole-genome sequencing may also identify driver mutations and modes of resistance to immunotherapies as well as other targeted therapies. Today, induction with a CD38 antibody, proteasome inhibitor, immunomodulatory drug, and dexamethasone, potentially followed by autologous stem cell transplantation and lenalidomide maintenance, can be considered standard of care for transplant-eligible (TE) patients with newly diagnosed MM (NDMM). That prolonged disease control and functional cure can be achieved in non-transplant-eligible (NTE) patients is currently emerging as a distinct possibility: data from phase III trials that incorporate a CD38 antibody into the treatment of NTE NDMM patients demonstrate impressive MRD negativity rates that appear sustained over several years. While the long-term durability of chimeric antigen receptor T cells, bi-specific antibodies and other immunotherapies are being evaluated, several clinical trials are now investigating their role in frontline treatment for TE and NTE patients. These trials will address whether chimeric antigen receptor T-cell therapy will replace autologous stem cell transplantation and whether such immunotherapies will represent a truly curative option. We conclude that while cure remains elusive, the concept of operational or functional cure provides a new benchmark to strive for and is an emerging area of active and potentially achievable clinical research for MM.<\/jats:p>","DOI":"10.3324\/haematol.2023.283058","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:27:10Z","timestamp":1707967630000},"page":"2420-2435","source":"Crossref","is-referenced-by-count":34,"title":["Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible"],"prefix":"10.3324","volume":"109","author":[{"given":"Monika","family":"Engelhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"64052","doi-asserted-by":"crossref","unstructured":"Van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021; 397(10272):410-427.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"64053","doi-asserted-by":"crossref","unstructured":"Hieke S, Kleber M, K\u00f6nig C, Engelhardt M, Schumacher M. Conditional survival: a useful concept to provide information on how prognosis evolves over time. Clin Cancer Res. 2015; 21(7):1530-1536.","DOI":"10.1158\/1078-0432.CCR-14-2154"},{"key":"64054","doi-asserted-by":"crossref","unstructured":"Schumacher M, Hieke S, Ihorst G, Engelhardt M. Dynamic prediction: a challenge for biostatisticians, but greatly needed by patients, physicians and the public. Biom J. 2020; 62(3):822-835.","DOI":"10.1002\/bimj.201800248"},{"key":"64055","doi-asserted-by":"crossref","unstructured":"Schinke M, Ihorst G, Duyster J, W\u00e4sch R, Schumacher M, Engelhardt M. Risk of disease recurrence and survival in patients with multiple myeloma: a German Study Group analysis using a conditional survival approach with long-term follow-up of 815 patients. Cancer. 2020; 126(15):3504-3515.","DOI":"10.1002\/cncr.32978"},{"key":"64056","doi-asserted-by":"crossref","unstructured":"Tralongo P, Maso LD, Surbone A. Use of the word \u201ccured\u201d for cancer patients\u2014implications for patients and physicians: the Siracusa charter. Curr Oncol. 2015; 22(1):e38-e40.","DOI":"10.3747\/co.22.2287"},{"key":"64057","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Palumbo A, Johnsen HE. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014; 99(6):984-996.","DOI":"10.3324\/haematol.2013.100552"},{"key":"64058","doi-asserted-by":"crossref","unstructured":"Musto P, Engelhardt M, Caers J. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica. 2021; 106(11):2799-2812.","DOI":"10.3324\/haematol.2021.278519"},{"key":"64059","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Dold SM, Ihorst G. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016; 101(9):1110-1119.","DOI":"10.3324\/haematol.2016.148189"},{"key":"64060","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Domm A-S, Dold SM. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017; 102(5):910-921.","DOI":"10.3324\/haematol.2016.162693"},{"key":"64061","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Ihorst G, Duque-Afonso J. Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica. 2020; 105(5):1183-1188.","DOI":"10.3324\/haematol.2019.242958"},{"key":"64062","doi-asserted-by":"crossref","unstructured":"Knop S, Engelhardt M, Liebisch P. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019; 33(11):2710-2719.","DOI":"10.1038\/s41375-019-0537-2"},{"key":"64063","doi-asserted-by":"crossref","unstructured":"Mohty M, Avet-Loiseau H, Harousseau J-L. Requirements for operational cure in multiple myeloma. Blood. 2021; 138(16):1406-1411.","DOI":"10.1182\/blood.2021012854"},{"key":"64064","unstructured":"Bence Jones H. Some account of a new animal substance occurring in the urine of a patient labouring under mollities ossium. Edinb Med Surg J. 1850; 74(185):357-368."},{"key":"64065","doi-asserted-by":"crossref","unstructured":"Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood. 1968; 31(1):1-10.","DOI":"10.1182\/blood.V31.1.1.1"},{"key":"64066","doi-asserted-by":"crossref","unstructured":"Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341(21):1565-1571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"64067","doi-asserted-by":"crossref","unstructured":"Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986; 67(5):1298-1301.","DOI":"10.1182\/blood.V67.5.1298.1298"},{"key":"64068","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Hoering A, Cavo M. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project. Blood Cancer J. 2018; 8(12):123.","DOI":"10.1038\/s41408-018-0155-7"},{"key":"64069","doi-asserted-by":"crossref","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020; 4(23):5988-5999.","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"64070","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"64071","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"64072","doi-asserted-by":"crossref","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017; 14(2):100-113.","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"64073","doi-asserted-by":"crossref","unstructured":"Dutta AK, Alberge J-B, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol. 2022; 19(4):223-236.","DOI":"10.1038\/s41571-021-00593-y"},{"key":"64074","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Stewart AK, Chanan-Khan A. Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood. 2013; 122(26):4172-4181.","DOI":"10.1182\/blood-2013-08-520890"},{"key":"64075","doi-asserted-by":"crossref","unstructured":"Boiarsky R, Haradhvala NJ, Alberge J-B. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun. 2022; 13(1):7040.","DOI":"10.1038\/s41467-022-33944-z"},{"key":"64076","doi-asserted-by":"crossref","unstructured":"Cohen YC, Zada M, Wang S-Y. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021; 27(3):491-503.","DOI":"10.1038\/s41591-021-01232-w"},{"key":"64077","doi-asserted-by":"crossref","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020; 1(5):493-506.","DOI":"10.1038\/s43018-020-0053-3"},{"key":"64078","doi-asserted-by":"crossref","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021; 27(4):616-619.","DOI":"10.1038\/s41591-021-01245-5"},{"key":"64079","doi-asserted-by":"crossref","unstructured":"Samur MK, Fulciniti M, Aktas Samur A. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021; 12(1):868.","DOI":"10.1038\/s41467-021-21177-5"},{"key":"64080","doi-asserted-by":"crossref","unstructured":"Friedrich MJ, Neri P, Kehl N. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023; 41(4):711-725.","DOI":"10.1016\/j.ccell.2023.02.008"},{"key":"64081","doi-asserted-by":"crossref","unstructured":"Andreozzi F, Dragani M, Quivoron C. Precision medicine approach based on molecular alterations for patients with relapsed or refractory multiple myeloma: results from the MM-EP1 study. Cancers. 2023; 15(5):1508.","DOI":"10.3390\/cancers15051508"},{"key":"64082","doi-asserted-by":"crossref","unstructured":"John L, Krauth MT, Podar K, Raab M-S. Pathway-directed therapy in multiple myeloma. Cancers. 2021; 13(7):1668.","DOI":"10.3390\/cancers13071668"},{"key":"64083","doi-asserted-by":"crossref","unstructured":"Andrulis M, Lehners N, Capper D. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013; 3(8):862-869.","DOI":"10.1158\/2159-8290.CD-13-0014"},{"key":"64084","doi-asserted-by":"crossref","unstructured":"Giesen N, Chatterjee M, Scheid C. A phase 2 clinical trial of combined BRAF\/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood. 2023; 141(14):1685-1690.","DOI":"10.1182\/blood.2022017789"},{"key":"64085","doi-asserted-by":"crossref","unstructured":"Richardson PG, Oriol A, Larocca A. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021; 39(7):757-767.","DOI":"10.1200\/JCO.20.02259"},{"key":"64086","doi-asserted-by":"crossref","unstructured":"Richardson PG, Trudel S, Popat R. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023; 389(11):1009-1022.","DOI":"10.1056\/NEJMoa2303194"},{"key":"64087","doi-asserted-by":"crossref","unstructured":"Richardson PG, p SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147.","DOI":"10.1056\/NEJMoa2204925"},{"key":"64088","doi-asserted-by":"crossref","unstructured":"Gay F, Musto P, Rota-Scalabrini D. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021; 22(12):1705-1720.","DOI":"10.1016\/S1470-2045(21)00535-0"},{"key":"64089","doi-asserted-by":"crossref","unstructured":"Moreau P, Attal M, Hulin C. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192):29-38.","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"64090","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.","DOI":"10.1182\/blood.2020005288"},{"key":"64091","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022; 40(25):2901-2912.","DOI":"10.1200\/JCO.21.01935"},{"key":"64092","unstructured":"Goldschmidt H, Mai EK, Bertsch U. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022; 9(11):e810-e821."},{"key":"64093","doi-asserted-by":"crossref","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA. Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomidedexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023; 142(Suppl 1):4.","DOI":"10.1182\/blood-2023-177546"},{"key":"64094","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024; 390(4):301-313.","DOI":"10.1056\/NEJMoa2312054"},{"key":"64095","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380(22):2104-2115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"64096","doi-asserted-by":"crossref","unstructured":"Facon T, Cook G, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022; 36(4):1066-1077.","DOI":"10.1038\/s41375-021-01488-8"},{"key":"64097","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022; 139(4):492-501.","DOI":"10.1182\/blood.2020010439"},{"key":"64098","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"64099","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Cavo M, Blade J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, openlabel, phase 3 trial. Lancet. 2020; 395(10218):132-141.","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"64100","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"64101","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"64102","doi-asserted-by":"crossref","unstructured":"Martin T, Usmani SZ, Berdeja JG. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022; 41(6):1265-1274.","DOI":"10.1200\/JCO.22.00842"},{"key":"64103","doi-asserted-by":"crossref","unstructured":"Mi J-Q, Zhao W, Jing H. Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023; 41(6):1275-1284.","DOI":"10.1200\/JCO.22.00690"},{"key":"64104","doi-asserted-by":"crossref","unstructured":"Mailankody S, Devlin SM, Landa J. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022; 387(13):1196-1206.","DOI":"10.1056\/NEJMoa2209900"},{"key":"64105","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Dhakal B, Yong K. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023; 389(4):335-347.","DOI":"10.1056\/NEJMoa2303379"},{"key":"64106","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023; 388(11):1002-1014.","DOI":"10.1056\/NEJMoa2213614"},{"key":"64107","doi-asserted-by":"crossref","unstructured":"Alqazaqi R, Schinke C, Thanendrarajan S. Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw Open. 2022; 5(8):e2228877.","DOI":"10.1001\/jamanetworkopen.2022.28877"},{"key":"64108","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Selder R, Pandurevic M. [Multidisciplinary tumor boards: facts and satisfaction analysis of an indispensable comprehensive cancer center instrument]. Dtsch Med Wochenschr. 2017; 142(9):e51-e60.","DOI":"10.1055\/s-0043-100054"},{"key":"64109","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Brioli A, von Lilienfeld-Toal M. [Differences due to socio-economic status, genetic background and sex in cancer and precision medicine - an intersectional approach to close the care gap for marginalized groups]. Dtsch Med Wochenschr. 2023; 148(9):528-538.","DOI":"10.1055\/a-1892-4833"},{"key":"64110","doi-asserted-by":"crossref","unstructured":"Frank B, Ihorst G, Herget G. Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers. Ann Hematol. 2023; 102(3):603-611.","DOI":"10.1007\/s00277-022-05051-y"},{"key":"64111","doi-asserted-by":"crossref","unstructured":"Moreau P, Touzeau C. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?. Blood. 2022; 139(26):3681-3687.","DOI":"10.1182\/blood.2021014611"},{"key":"64112","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387(6):495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"64113","doi-asserted-by":"crossref","unstructured":"Chari A, Minnema MC, Berdeja JG. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022; 387(24):2232-2244.","DOI":"10.1056\/NEJMoa2204591"},{"key":"64114","doi-asserted-by":"crossref","unstructured":"Ludwig H, Terpos E, van de Donk N. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023; 24(6):e255-e269.","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"64115","doi-asserted-by":"crossref","unstructured":"Larocca A, Dold SM, Zweegman S. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018; 32(8):1697-1712.","DOI":"10.1038\/s41375-018-0142-9"},{"key":"64116","doi-asserted-by":"crossref","unstructured":"Straka C, Liebisch P, Salwender H. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016; 101(11):1398-1406.","DOI":"10.3324\/haematol.2016.151860"},{"key":"64117","doi-asserted-by":"crossref","unstructured":"Straka C, Schaefer-Eckart K, Hertenstein B. Long-term outcome of a prospective randomized trial comparing continuous lenalidomide\/dexamethasone with lenalidomide\/ dexamethasone induction, MEL140 with autologous blood stem cell transplantation and single agent lenalidomide maintenance in patients of age 60-75 years with newly diagnosed multiple myeloma. Blood. 2022; 140(Suppl 1):287-288.","DOI":"10.1182\/blood-2022-159357"},{"key":"64118","unstructured":"Houde CA, Khan A, Jacobus SJ. Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial. Blood. 2023; 142(Suppl 1):4762."},{"key":"64119","doi-asserted-by":"crossref","unstructured":"Mian H, McCurdy A, Giri S. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J. 2023; 13(1):6.","DOI":"10.1038\/s41408-022-00779-2"},{"key":"64120","doi-asserted-by":"crossref","unstructured":"Holler M, Ihorst G, Reinhardt H. An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence. Haematologica. 2023; 108(4):1115-1126.","DOI":"10.3324\/haematol.2022.281489"},{"key":"64121","doi-asserted-by":"crossref","unstructured":"Facon T, Cook G, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022; 36(4):1066-1077.","DOI":"10.1038\/s41375-021-01488-8"},{"key":"64122","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021; 21(11):785-798.","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"64123","doi-asserted-by":"crossref","unstructured":"Terpos E, Mikhael J, Hajek R. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021; 11(2):40.","DOI":"10.1038\/s41408-021-00432-4"},{"key":"64124","doi-asserted-by":"crossref","unstructured":"Rajeeve S, Usmani SZ. How old is too old for CAR-T cell therapies in multiple myeloma?. Transplant Cell Ther. 2023; 29(6):343-344.","DOI":"10.1016\/j.jtct.2023.05.001"},{"key":"64125","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell EK, Shapiro YN, Yee AJ. Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022; 128(10):1996-2004.","DOI":"10.1002\/cncr.34134"},{"key":"64126","doi-asserted-by":"crossref","unstructured":"M\u00f6ller M-D, Ihorst G, Pahl A. Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation. J Geriatr Oncol. 2021; 12(4):521-530.","DOI":"10.1016\/j.jgo.2020.11.003"},{"key":"64127","doi-asserted-by":"crossref","unstructured":"M\u00f6ller M-D, Gengenbach L, Graziani G, Greil C, W\u00e4sch R, Engelhardt M. Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?. Curr Opin Oncol. 2021; 33(6):648-657.","DOI":"10.1097\/CCO.0000000000000792"},{"key":"64128","doi-asserted-by":"crossref","unstructured":"Tang L, Pan Z, Zhang X. The effect of marital status on the survival of patients with multiple myeloma. Hematology. 2022; 27(1):187-197.","DOI":"10.1080\/16078454.2022.2026027"},{"key":"64129","doi-asserted-by":"crossref","unstructured":"Terpos E, Zamagni E, Lentzsch S. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021; 22(3):e119-e130.","DOI":"10.1016\/S1470-2045(20)30559-3"},{"key":"64130","doi-asserted-by":"crossref","unstructured":"Shah UA, Parikh R, Castro F, Bellone M, Lesokhin AM. Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders. Leukemia. 2023; 37(5):964-980.","DOI":"10.1038\/s41375-023-01874-4"},{"key":"64131","doi-asserted-by":"crossref","unstructured":"Shah UA, Maclachlan KH, Derkach A. Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets. Clin Cancer Res. 2022; 28(23):5149-5155.","DOI":"10.1158\/1078-0432.CCR-22-0723"},{"key":"64132","doi-asserted-by":"crossref","unstructured":"Vernieri C, Fuc\u00e0 G, Ligorio F. Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer. Cancer Discov. 2022; 12(1):90-107.","DOI":"10.1158\/2159-8290.CD-21-0030"},{"key":"64133","doi-asserted-by":"crossref","unstructured":"Sheu M, Molina Garcia S, Patel M. Intravenous immunoglobulin prophylaxis is associated with decreased rate of infection-related hospitalizations in multiple myeloma patients. Hematol Oncol. 2023; 41(4):718-724.","DOI":"10.1002\/hon.3185"},{"key":"64134","doi-asserted-by":"crossref","unstructured":"Gupta VA, Barwick BG, Matulis SM. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021; 137(26):3604-3615.","DOI":"10.1182\/blood.2020007899"},{"key":"64135","doi-asserted-by":"crossref","unstructured":"Raab MS, Lehners N, Xu J. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood. 2016; 127(17):2155-2157.","DOI":"10.1182\/blood-2015-12-686782"},{"key":"64136","doi-asserted-by":"crossref","unstructured":"Rasche L, Chavan SS, Stephens OW. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017; 8(1):268.","DOI":"10.1038\/s41467-017-00296-y"},{"key":"64137","doi-asserted-by":"crossref","unstructured":"Rasche L, Schinke C, Maura F. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022; 13(1):4517.","DOI":"10.1038\/s41467-022-32145-y"},{"key":"64138","doi-asserted-by":"crossref","unstructured":"Merz M, Merz AMA, Wang J. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nat Commun. 2022; 13(1):807.","DOI":"10.1038\/s41467-022-28266-z"},{"key":"64139","doi-asserted-by":"crossref","unstructured":"Merz M, Hu Q, Merz AMA. Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma. Blood Adv. 2023; 7(5):718-733.","DOI":"10.1182\/bloodadvances.2022007457"},{"key":"64140","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"},{"key":"64141","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Allen C, Barac A. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018; 4(9):1221.","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"64142","doi-asserted-by":"crossref","unstructured":"Scheubeck S, Ihorst G, Schoeller K. Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort. Cancer. 2021; 127(18):3422-3436.","DOI":"10.1002\/cncr.33658"},{"key":"64143","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Nooka AK, Larson SM. Moving toward a cure for myeloma. Am Soc Clin Oncol Educ Book. 2022; 42:1-12.","DOI":"10.1200\/EDBK_349603"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283058\/76608","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283058\/77336","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11443\/76608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:45Z","timestamp":1794045945000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":92,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283058","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}